🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

33 results for “Actemra” Clear

  1. Bendamustine 100 mg Powder for concentrate for Solution for Infusion, Truxima 100 mg concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion, PREDNISONE BIOGARAN 20 mg, scored tablet, Cyclophosphamide Injection 500 mg., Doxorubicin 2 mg/ml Solution for Injection., Truxima 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Revlimid 5 mg hard capsules, Epcoritamab (GEN3013), Epcoritamab (GEN3013), Revlimid 20 mg hard capsul

    AbbVie Deutschland GmbH & Co. KG

    Follicular Lymphoma

    phase 3 small molecule active

    1 trial

  2. METHYLPREDNISOLONE , CellCept 500 mg film-coated tablets, PREDNISONE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , ANAKINRA , RoActemra 20 mg/mL concentrate for solution for infusion, DEXAMETHASONE , Acasunlimab

    Genmab A/S

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  3. MabThera 500 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Glofitamab, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed or refractory diffuse large B-cell lymphoma

    phase 3 small molecule active

    1 trial

  4. RITUXIMAB, METHOTREXATE, MYCOPHENOLATE MOFETIL, RoActemra 162 mg solution for injection in pre-filled pen., AZATHIOPRINE, XELJANZ 5 mg film-coated tablets

    Pari Pharma GmbH

    Patients with GPA and inadequate response to standard of care therapy defined as an inadequate response to either a combination of glucocorticoids plus cyclophosphamide AND/OR a combination of glucocorticoids plus rituximab.

    phase 3 small molecule active

    1 trial

  5. RoActemra 20 mg/mL concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Neulasta 6 mg solution for injection, AZD0486, RoActemra 20 mg/mL concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Ribodoxo® 2 mg/ml Injektionslösung, Prednison 20 mg GALEN®, AZD0486, Endoxan 500 mg, poeder voor oplossing voor injectie, Ruxience 500 mg concentrate for solution for infusion

    AstraZeneca AB

    Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  6. RoActemra 20 mg/mL concentrate for solution for infusion, Tofidence 20 mg/mL concentrate for solution for infusion, Avtozma 20 mg/mL concentrate for solution for infusion., SODIUM CHLORIDE, Tyenne 20 mg/ml concentrate for solution for infusion

    Pari Pharma GmbH

    Chondrocalcinosis

    phase 3 small molecule active

    1 trial

  7. Tecentriq 1 200 mg concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BI 764532, RoActemra 20 mg/mL concentrate for solution for infusion

    Boehringer Ingelheim

    small cell lung cancer

    phase 3 small molecule active

    1 trial

  8. Upadacitinib, RoActemra 162 mg solution for injection in pre-filled syringe., RoActemra 162 mg solution for injection in pre-filled pen., Upadacitinib, RoActemra 20 mg/mL concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  9. tocilizumab [RoActemra/Actemra]

    Hoffmann-La Roche

    Rheumatoid Arthritis

    phase 3 small molecule completed

    3 trials

  10. -, CYCLOPHOSPHAMIDE, Cesnicabtagene autoleucel, PARACETAMOL, FLUDARABINE, LENALIDOMIDE, RoActemra 20 mg/mL concentrate for solution for infusion

    The George Institute

    Plasma cell leukaemia

    phase 2 small molecule active

    1 trial

  11. Abraxane 5 mg/ml powder for dispersion for infusion., Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, RoActemra 20 mg/mL concentrate for solution for infusion, Gemcitabin AqVida 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Gemcitabin Kabi 38 mg/ml Pulver zur Herstellung einer Infusionslösung, Avastin 25 mg/ml concentrate for solution for infusion., ATEZOLIZUMAB, Tiragolumab

    Hoffmann-La Roche

    Pancreatic ductal adenocarcinoma (PDAC)

    phase 2 small molecule active

    1 trial

  12. Cevostamab, RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  13. Columvi 10 mg concentrate for solution for infusion, Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., RoActemra 20 mg/mL concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)

    phase 2 small molecule active

    1 trial

  14. DEXAMETHASONE , PEGFILGRASTIM , Mosunetuzumab, DIPHENHYDRAMINE , RASBURICASE , Polivy 140 mg powder for concentrate for solution for infusion., Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion, Mosunetuzumab, Mosunetuzumab, PREDNISONE , FLUDEOXYGLUCOSE (18F) , METHYLPREDNISOLONE, MabThera 500 mg concentrate for solution for infusion, PARACETAMOL, ALLOPURINOL

    Hoffmann-La Roche

    B-cell non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  15. Dexamethasone 4 mg tablets, Cytarabine 20 mg/ml Solution for Injection or Infusion, Calquence 100 mg hard capsules, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Histergan Tablets, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, Mesna Injection, Methylprednisolone 1000 mg powder and solvent for solution for injection/infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Panadol 50

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  16. Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Paracetamol 500 mg Film-Coated Tablets, Diluent for REGN5458, Linvoseltamab, Diphenhydramine Hydrochloride 25 mg Tablets, Dermodrin 30 mg/2 ml soluție injectabilă, Dexamethasone 4 mg tablets, RoActemra 20 mg/mL concentrate for solution for infusion, Linvoseltamab

    Lacuna Pharma Pty Ltd

    Relapsed or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  17. Fludarabina Accord 25 mg/ml concentrado para solución inyectable y para perfusión., HSP-CAR30, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, RoActemra 20 mg/mL concentrate for solution for infusion, Genoxal 200 mg polvo para solución inyectable y para perfusión

    The George Institute

    Refractary or relapse non-Hodgkin T CD30+ lymphoma., Refractary or relapse Hodgkin T CD30+ lymphoma

    phase 2 small molecule active

    1 trial

  18. IFOSFAMIDE , MabThera 500 mg concentrate for solution for infusion, ETOPOSIDE , Gazyvaro 1,000 mg concentrate for solution for infusion., CD20 CD3 TCB, RoActemra 20 mg/mL concentrate for solution for infusion, CARBOPLATIN

    Hoffmann-La Roche

    CD20 positive B-Cell Non-Hodgkin Lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  19. INFLIXIMAB, RoActemra 20 mg/mL concentrate for solution for infusion

    Pari Pharma GmbH

    Takayasu arteritis

    phase 2 small molecule active

    1 trial

  20. Iberdomide, Iberdomide, Cevostamab, Iberdomide, Revlimid 10 mg hard capsules, RoActemra 20 mg/mL concentrate for solution for infusion, Iberdomide, Revlimid 5 mg hard capsules

    Hoffmann-La Roche

    Multiple Myeloma (MM)

    phase 2 small molecule active

    1 trial

  21. JNJ-64407564, RoActemra 20 mg/mL concentrate for solution for infusion, JNJ-64407564, JNJ-64407564, Tyenne 20 mg/ml concentrate for solution for infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Tyenne 20 mg/ml concentrate for solution for infusion, JNJ-64407564

    Janssen-Cilag International N.V.

    Multiple myeloma

    phase 2 small molecule active

    1 trial

  22. Levact 2,5 mg/ml, polvo para concentrado para solución para perfusión., Beneflur10 mg comprimidos recubiertos con película, RoActemra 20 mg/mL concentrate for solution for infusion, Genoxal 200 mg polvo para solución inyectable y para perfusión, HSP-CAR19M

    The George Institute

    Relapsed/refractory large B-cell non-Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma

    phase 2 small molecule active

    1 trial

  23. Linvoseltamab, Diphenhydramine Hydrochloride 25 mg Tablets, RoActemra 20 mg/mL concentrate for solution for infusion, Dexamethasone 4 mg tablets, Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Paracetamol 500 mg Film-Coated Tablets

    Lacuna Pharma Pty Ltd

    High-Risk Monoclonal Gammopathy of Undetermined Significance; Non-High-Risk Smoldering Multiple Myeloma

    phase 2 small molecule active

    1 trial

  24. Linvoseltamab, Linvoseltamab, RoActemra 20 mg/mL concentrate for solution for infusion, Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Diphenhydramine Hydrochloride 25 mg Tablets, Paracetamol 500mg Tablets, REGN88, Dexamethasone 2mg Tablets

    Lacuna Pharma Pty Ltd

    Relapsed or Refractory Systemic Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources